gilead has released info about
sofosbuvir and pre and post transplant patients from phase 2 study. patients who treated for 24 weeks of sofo/riba, had these results. 95% of post trans patients completed study. there were no deaths, no graft losses, and no organ rejection. next week gilead will give more data at the liver foundation meetings, on clearance rates. this should ease the minds of drs treating recurrences. adding Ledi will only make it more successful. barry
Post Edited By Moderator (hep93) : 11/8/2013 3:36:16 PM (GMT-7)